← Back to Treatments
🏅 FDA Orphan Designation

Enjaymo

SUTIMLIMAB-JOME

Manufacturer: Recordati Rare Diseases, Inc.

Indicated for:
Neonatal autoimmune hemolytic anemiaOrphanCold agglutinin disease

FDA-Approved Indications (2)

To decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD)

indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD)

Population: adults

Indications & Usage

1 INDICATIONS AND USAGE ENJAYMO is a classical complement inhibitor indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD). ( 1 ) Cold Agglutinin Disease ENJAYMO (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD).

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.